VC Firm Flagship Commits $50M To Gene Control Researcher
The life sciences-focused venture capital firm Flagship Pioneering has committed $50 million to a Massachusetts-based pharmaceutical research and development company that specializes in treating cancer and rare diseases, Flagship said Wednesday....To view the full article, register now.
Already a subscriber? Click here to view full article